Loading…
← CockpitCompetitor Analysis › 600196.SS Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A600196.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Diversified Chinese pharma group making generics and innovative drugs and distributing medicines and devices nationwide.

≈ A Chinese cross between Sanofi and McKesson (mfg + distribution)Momentum strong 63
Mkt cap
$7.57B
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$65.8M
20-day average traded
Fwd P/E
14.8×
forward earnings
ROIC−WACC
-1.1 pp
WACC 5.0%
Hurdle
-4 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥20.82
1D+0.1%
1W-9.2%
1M-10.0%
3M-14.8%
6M-13.7%
YTD-21.4%
1Y-26.4%
ATR %3.1%
52w lowhigh28.5% off high

What Shanghai Fosun Pharmaceutical (Group) does

Diversified Chinese pharma group making generics and innovative drugs and distributing medicines and devices nationwide.

Combines drug manufacturing, medical devices and hospitals with a pharmaceutical distribution business that earns thin margins on large volume. It holds a large minority stake in Sinopharm, China's biggest drug distributor. Its parent, the Fosun International investment conglomerate, controls it.

In one line: A Chinese cross between Sanofi and McKesson (mfg + distribution).

Products and services

  • Generic & branded pharmaceuticals
  • Innovative drugs (oncology, biologics)
  • Pharma & device distribution
  • Diagnostics

Customers

  • Hospitals
  • Pharmacies
  • Distributors

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals
  • Generics, innovation & distribution

What could go right

  • Innovative drug pipeline maturing
  • Expansion of biosimilar portfolio

What could go wrong

  • National drug price cuts (VBP)
  • Generic price competition

Moat: narrow (distribution, scale, regulatory licence). Broad national distribution network and manufacturing scale under the Fosun Group umbrella.

Headquarters: Shanghai, China · Founded: 1994 · Employees: 40,603

Named competitors

Shanghai Fosun Pharmaceutical (Group) at a glance

Size Shanghai Fosun Pharmaceutical (Group) (600196.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $7.57B, the 309th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥20.82 on 18 Nov 2026.

Performance Over six months the shares fell 13.7%, against +4.4% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 8.1% over the last twelve months (peer median +13.9%); the operating margin is 6.4% (peer median 16.4%).

Valuation It trades at 14.8× forward earnings against a peer median of 23.3× (4th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.1 points below its cost of capital (5.0% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 107600196.SS 87
Six months, rebased to 100: Shanghai Fosun Pharmaceutical (Group) against the median of its 20 peers (local-currency closes).

Shanghai Fosun Pharmaceutical (Group) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥42.7BCN¥41.5BCN¥40.9BCN¥41.3BCN¥43.8B
Revenue growth—+1%-1%-6%—
Gross profitCN¥23.5BCN¥19.1BCN¥18.1BCN¥18.1BCN¥19.5B
EBITDAn/aCN¥6.10BCN¥5.78BCN¥3.96BCN¥5.57B
Net incomeCN¥3.51BCN¥3.37BCN¥2.77BCN¥2.39BCN¥3.73B
Free cash flowCN¥493MCN¥1.56BCN¥1.16B-CN¥973M-CN¥853M
Capital expenditureCN¥5.55BCN¥4.45BCN¥4.41BCN¥5.34BCN¥5.89B
Total debtCN¥41.5BCN¥36.7BCN¥36.7BCN¥35.7BCN¥31.1B

Quarterly statements and history in the cockpit →

Shanghai Fosun Pharmaceutical (Group) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%AMRXGRFKNSACORT4528ALKS002821ALK-BGLENMARKCYTKIBRXBANB9926RYTMPTGX4151PRAX000963600196.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Fosun Pharmaceutical (Group) is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×AMRXGRFKNSACORT002821PTGX600196.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Fosun Pharmaceutical (Group) is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%AMRXGRFKNSACORT4528ALKSALK-BGLENMARK601607PTGX000963ALKEM600196.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Fosun Pharmaceutical (Group) is the large dot.

Shanghai Fosun Pharmaceutical (Group) competitors and peer comparison

Head to head with its named competitors (600196.SS vs 601607.SS vs 1177.HK vs 3320.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai Fosun Pharmaceutical (Group) 600196.SS$7.57B-14%+8%6%14.8×2.9%
Shanghai Pharmaceuticals 601607.SS$8.23B0%+4%3%11.2×-10.1%
Sbp 1177.HK$12.2B+5%+15%30%17.5×-5.7%
China Resources Pharmaceutical 3320.HK$3.60B-7%+8%4%5.8×-4.9%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%

How Shanghai Fosun Pharmaceutical (Group) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Fosun Pharmaceutical (Group) against its 20 peers (data as of 18 Nov 2026)
Measure600196.SSPeer medianRank in peer set
1-month return-10.0%+2.2%5th lowest of 21
6-month return-13.7%+4.4%5th lowest of 21
Distance from 52-week high-28.5%-11.6%7th lowest of 21
Revenue growth (TTM)+8.1%+13.9%8th lowest of 21
Operating margin6.4%16.4%7th lowest of 20
Forward P/E14.8×23.3×4th cheapest of 15
Growth the price implies (Req g, 7 yrs)2.9%10.4%5th least demanding of 14
Growth delivered (Del g)+6.6%+9.4%2nd lowest of 14
Hurdle (Req g minus delivered)-3.7 pp-0.0 pp7th least demanding of 14
ROIC minus cost of capital-1.1 pp+1.7 pp6th lowest of 19
Net debt / EBITDA3.7×-0.3×4th most indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%14.8×2.9%+6.6%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%

Questions

Who are Shanghai Fosun Pharmaceutical (Group)'s main competitors?
Named competitors: Shanghai Pharmaceuticals (601607.SS), Sino Biopharm (1177.HK), China Resources Pharma (3320.HK), Jiangsu Hengrui (600276.SS). The cockpit's measured peer set (industry) also includes Amneal Pharmaceuticals (AMRX), Grifols (GRF.MC), Kiniksa Pharmaceuticals International (KNSA), Corcept Therapeutics (CORT), ONO Pharmaceutical (4528.T), Alkermes Public (ALKS).
Is Shanghai Fosun Pharmaceutical (Group) expensive compared with its peers?
On forward p/e it trades at 14.8× against a peer median of 23.3×, 4th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Shanghai Fosun Pharmaceutical (Group) stock performed?
Over six months to 18 Nov 2026 the shares returned -13.7% against +4.4% for the median peer; over one year -26.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.